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A tumor-targeted trimeric 4-1BB-agonistic antibody
induces potent anti-tumor immunity without
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The costimulation of immune cells using ﬁrst-generation anti-4-1BB monoclonal antibodies
(mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development,
however, is restricted by signiﬁcant off-tumor toxicities associated with FcγR interactions.
Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1,
consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-
domain antibodies positioned in an extended hexagonal conformation around the collagen
XVIII homotrimerization domain. The1D8N/CEGa1 trimerbody demonstrated high-avidity
binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of
EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor
activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8N/CEGa1
does not induce systemic inﬂammatory cytokine production or hepatotoxicity associated with
IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-
associated immune abnormalities, and promote the use of the non-canonical antibody pre-
sented in this work for safe and effective costimulatory strategies in cancer immunotherapy.
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Modulating immune responses using monoclonal anti-bodies (mAbs) is a promising approach to cancertherapy. Antagonistic mAbs directed against checkpoint
inhibitors such as cytotoxic T-lymphocyte–associated antigen 4
and programmed cell death 1/programmed cell death ligand 1
(PD-L1) have been clinically approved, and agonistic mAbs tar-
geting costimulatory receptors are undergoing clinical trials1.
Costimulatory receptors of the tumor necrosis factor (TNF)
receptor superfamily (TNFRSF), such as CD40, OX40, and 4‐1BB,
are particularly interesting targets, as these receptors are not
constitutively expressed on resting naive T cells but acquired
upon activation2–4. This limits the potential deleterious side
effects of the treatment5.
4-1BB (CD137, TNFRSF9) has only one conﬁrmed ligand
[4-1BB-Ligand (4-1BBL), TNFSF9], which is expressed on mac-
rophages, activated B cells, and dendritic cells6. Engagement of
4-1BB by its ligand or an agonistic antibody promotes T cell
proliferation, cytokine production, and cytolytic effector func-
tions and protects lymphocytes from programmed cell death7,8.
Furthermore, engagement of 4-1BB on natural killer cells
enhances cytokine release (including interferon (IFN)-γ)9and
antibody-dependent cellular cytotoxicity10,11. Indeed, treatment
of mice with 4-1BB-agonistic mAbs was found to induce tumor
regression of established and poorly immunogenic tumors as
early as 199712. Since then, a large body of accumulated pre-
clinical data has been gathered that supports the induction of 4-
1BB signaling in cancer immunotherapy, both as a single agent
and in combination therapies13.
The effect of 4-1BB-agonistic mAbs is not spatially restricted to
the tumor, and peripheral toxicities can therefore reduce the
therapeutic window for 4-1BB-targeting therapies. In mice, 4-1BB
mAbs have been shown to cause immune anomalies, notably
polyclonal activation of CD8+ T cells and secretion of inﬂam-
matory cytokines, which affected the function of liver, spleen, and
bone marrow14,15. In clinical studies, an anti-4-1BB mAb (BMS-
663513, urelumab) showed tolerable side effects in an initial
Phase I trial, but a follow-up Phase II trial revealed severe liver
toxicity in ≈10% of the patients that resulted in two fatalities16. As
a consequence, trials with urelumab were terminated17. Recently,
data were presented on a dose-escalation study with urelumab as
monotherapy and in combination with nivolumab18. The reduced
dose ameliorated liver toxicity; however, the clinical activity of
urelumab at the tolerated dose was limited. An integrated safety
analysis of patients treated with urelumab conﬁrmed a clear
association between transaminitis and urelumab dose19. Utomi-
lumab is another anti-41BB mAb in clinical trials with a better
safety proﬁle than urelumab but is a relatively less potent 4-1BB
agonist20.
As it stands, costimulation by 4-1BB-agonistic mAbs is an
otherwise viable therapeutic approach held back by off-tumor
toxicities and could therefore beneﬁt greatly from the addition of
tumor-targeting functionality to restrict its effect to the tumor
deposits. Furthermore, if this is conveyed by binding domains
speciﬁc to cell surface tumor-associated antigens (TAAs), the
anti-4-1BB antibodies will then cluster on the surface of cancer
cells. This may allow the antibodies to mimic physiological 4-
1BBL and could have a major impact on the induction of 4-1BB
signaling. Importantly, 4-1BBL is a trimeric membrane protein
and can be proteolytically processed into soluble trimeric ligands
with a signiﬁcantly reduced signaling activity compared to their
transmembrane counterparts21. Signaling can be restored by
higher-order oligomerization21,22, cell surface display of anti-4-
1BB single chain antibody fragments (scFv) expressed by tumor
cells in fusion with membrane proteins23,24, or antibody-
mediated display by fusing the extracellular domain of 4-1BBL
to a TAA-speciﬁc scFv25. Another strategy is the use of anti-4-
1BB oligonucleotide aptamers instead of 4-1BBL26,27. In animal
models, systemic delivery of a 4-1BB-agonistic aptamer con-
jugated to a prostate-speciﬁc membrane antigen aptamer led to
superior therapeutic effect compared to immunoglobulin G
(IgG)-based 4-1BB-agonistic antibodies26. It has also been
recently reported that anchoring anti-4-1BB F(ab′)2 fragments
and interleukin (IL)-2 on the surface of liposomes induced
effective antitumor immunity without systemic toxicity28.
In this article, we describe the adaptation of the ﬁrst-generation
4-1BB agonistic IgG 1D8 to a recombinant antibody format, the
trimerbody. This format is based on the fusion of antibody-
derived binding domains to the small homotrimerization
region from murine collagen XVIII, which yields trimeric
antibodies29–31. Trimerbodies have two major advantages com-
pared to the IgG mAb: they lack the fragment crystallizable (Fc)
region involved in 4-1BB-mediated toxicity20; and they are tri-
meric, as is physiological 4-1BBL. We generated a panel of 1D8
scFv-based N-terminal trimerbodies (1D8N) using linkers of
different lengths and identiﬁed 1D8N18, the trimerbody with the
longest linker, as showing the most potent costimulatory activity.
1D8N18 was therefore used as the basis for a bispeciﬁc tumor-
targeted trimerbody, 1D8N/CEGa1, by adding the epidermal
growth factor receptor (EGFR)-binding EGa1 single-domain
antibody32. Compared to both 1D8 IgG and 1D8N18, 1D8N/
CEGa1 was a more potent costimulator in vitro and showed
enhanced tumor homing and tumor inhibition in vivo, with no
indication of the 4-1BB mAb-associated toxicity.
Results
Design of 4-1BB-agonistic trimerbodies. Using the scFv derived
from the rat IgG2a, anti-4-1BB 1D8 mAb33 (Fig. 1a), we designed
a panel of 1D8 scFv-based N-terminal trimerbodies (1D8N).
Three candidates were generated with varied lengths of the ﬂex-
ible linker connecting the 1D8 scFv to a murine collagen XVIII-
derived homotrimerization (TIEXVIII) domain: 1D8N0 has no
linker, while 1D8N5 and 1D8N18 have 5- and 18-residue-long
linkers, respectively (Fig. 1b). All three constructs were expressed
by transfected HEK293 cells at similar levels to MFE-23N18, a
benchmark N-terminal trimerbody based on the anti-CEA MFE-
23 scFv29. In western blot analysis under reducing conditions, the
1D8N trimerbodies were single-chain-type molecules with a
migration pattern consistent with the molecular weights calcu-
lated from their amino acid sequences (34.4, 34.7, and 36.8 kDa,
in the order of increasing linker length) (Supplementary Fig-
ure 1a). Additionally, they speciﬁcally recognized murine 4-1BB
in fusion with human Fc (m4-1BB) immobilized on plastic, as
determined by enzyme-linked immunosorbent assay (ELISA;
Supplementary Figure 1b).
The three 4-1BB-speciﬁc trimerbodies were produced in stably
transfected HEK293 cells and puriﬁed by immobilized metal
afﬁnity chromatography, with a yield of roughly 1 mg/l of
conditioned medium (Supplementary Figure 2a). Their binding
kinetics were then studied using biolayer interferometry (BLI).
While all 1D8 antibodies showed low picomolar-range KD toward
m4-1BB immobilized on biosensors, the 1D8N trimerbodies were
found to dissociate at approximately half the rate of the parental
1D8 mAb (Fig. 2a, Supplementary Table 1). This indicates that
the 1D8N trimerbodies are in fact functionally trivalent and
therefore have a higher functional afﬁnity than the bivalent 1D8
IgG. Furthermore, 1D8N18, 1D8N5, and 1D8N0 showed extremely
similar kinetic rate constants, indicating that none of the linker
length variations structurally compromise the 1D8 scFv or
sterically hinder its access to antigen. The ability of 1D8N
trimerbodies to detect m4-1BB in a cellular context was studied
by ﬂow cytometry. All 1D8N trimerbodies bound to HEK293 cells
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transfected to express murine 4-1BB on their cell surface
(HEK293m4-1BB) but not to untransfected HEK293 cells (Supple-
mentary Figure 2b). The binding of 1D8N0 to HEK293m4-1BB cells
was less efﬁcient than that of the 1D8N5 and 1D8N18
(Supplementary Figure 2b). 1D8N5, 1D8N18, and 1D8 IgG all
bound to activated mouse CD8a+ T cells but did not bind the
unstimulated T cells (Fig. 2b). The binding of 1D8N5 and 1D8N18
was competitively inhibited by 1D8 IgG (Supplementary
Figure 2c). These results show that the 1D8N trimerbodies retain
the ability to bind to endogenous murine 4-1BB.
We proceeded to investigate the costimulatory capability of the
1D8N trimerbodies by testing their effect on the proliferation, IFN-
γ secretion, and viability of mouse CD8a+ T cells in the presence of
a suboptimal dose of anti-CD3 mAb. 1D8 IgG and 1D8N18
increased proliferation (P = 0.0163 and P = 0.0013, respectively)
and IFN-γ secretion (P = 0.0092 and P = 0.0101, respectively)
similarly to each other (Fig. 2c, d), and 1D8N18 was signiﬁcantly
more potent than 1D8N5 and 1D8N0 (P = 0.0234 and P = 0.0016,
respectively; Fig. 2c). After 72 h, a statistically signiﬁcant increased
viability of CD8a+ T cells stimulated with 1D8 IgG and 1D8N18
was observed (P = 0.005 and P = 0.015, respectively; Fig. 2e).
Furthermore, 1D8N18 was signiﬁcantly more potent than 1D8 IgG
(P = 0.046; Fig. 2e). The recombinant soluble mouse 4-1BBL (m4-
1BBL) was essentially inactive (Fig. 2c, e). The m4-1BBL migrates
at approximately 40 kDa in reducing conditions and at
approximately 70 kDa in non-reducing conditions, compatible
with a trimer (Supplementary Figure 3a). The binding to m4-1BB
expressed on the cell surface was less efﬁcient than the 1D8N18
(Supplementary Figure 3b), and competition ELISA demonstrated
that m4-1BBL and 1D8N18 recognize different regions of the m4-
1BB (Supplementary Figure 3c). Next, we investigated the spatio-
temporal distribution and dynamics of the interactions between
cell surface m4-1BB and CF488A-labeled m4-1BBL, 1D8 IgG or
1D8N18 (Supplementary Figure 4) in living HEK293m4-1BB-S cells
displaying homogenous expression of the receptor (Supplementary
Figure 5). Employing raster imaging correlation spectroscopy
(RICS)34, we observed and quantiﬁed receptor clustering and its
molecular mobility upon binding. We observed that m4-1BBL does
not induce receptor clustering but rather internalization of the
receptor into the cytoplasm (≈70 μm2/s) (Supplementary Figure
6a). In contrast, both 1D8 IgG and 1D8N18 induce cluster
formation, reducing the lateral mobility drastically at the plasma
membrane upon binding, from ≈1.5 to 0.35 and from ≈1.0 to 0.15
μm2/s, respectively (Fig. 2f and Supplementary Figure 6b, c).
1D8N18 formed larger and more numerous membrane clusters,
which consequently impeded the lateral diffusion to a greater
degree, which indicates more effective and extensive crosslinking
(Fig. 2g).
As the 1D8N18 demonstrated improved T cell costimulatory
activity and induced receptor clustering to a greater degree, we
chose this particular conﬁguration for subsequent studies. We
used size exclusion chromatography with multi-angle light
scattering (SEC-MALS) to investigate the oligomeric state of
1D8N18. It eluted as a major symmetric peak with a mass of 112
kDa (Supplementary Figure 7a), close to the predicted 110.1 kDa
of 1D8N18 without signal sequence (mass spectrometry by matrix
assisted laser desorption/ionization (MALDI) conﬁrmed its
absence). Two minor peaks were also detected, the smallest being
a protein impurity, as seen by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE; Supplementary
Figure 7b). The other peak migrates in SDS-PAGE as 1D8N18 but
has a native mass of 244 kDa, probably corresponding to
trimer–dimers. The two species can be separated by SEC, but
reinjection of the major peak gives another minor trimer–dimer
peak (Supplementary Figure 7c), indicating an equilibrium where
the trimeric species are predominant (85% and 97% at 1.0 and
0.26 g/l, respectively). The circular dichroism spectrum of 1D8N18
(Supplementary Figure 7d) is typical of proteins with predomi-
nantly β-sheet structure. The 1D8N18 is folded into a stable three-
dimensional structure, as shown by the cooperative thermal
denaturation (Tm ≈ 57 °C; Supplementary Figure 7e). To
understand the behavior and structure of 1D8N18 in solution,
we analyzed it in the absence of substrate using small-angle X-ray
scattering (SAXS) (Fig. 2h and Supplementary Figure 7f, g,
Supplementary Table 2). The ab initio model shows how
the homotrimer adopts a pyramidal conformation stabilized
by direct interactions between the C-terminal TIEXVIII domains,
as has previously been described for human collagenXVIII35. The
1D8 scFvs point orthogonally away from the plane deﬁned by the
trimerization domain without directly contacting each other, in a
manner resembling an open tripod (Fig. 2h).
Design of an EGFR-targeted 4-1BB-agonistic trimerbody. We
proceeded to generate a bispeciﬁc trimerbody by fusing the anti-
human EGFR single-domain antibody (VHH; EGa1)32to the C-
terminus of 1D8N18 through a 17-residue-long linker giving the
1D8N/CEGa1 trimerbody (Fig. 1c). The construct was designed
with a FLAG and a StrepII tag at the N-terminus of the 1D8 scFv.
The 1D8N/CEGa1 was produced in stably transfected HEK293
cells (5 mg/l), followed by Strep-Tactin afﬁnity chromatography.
SDS-PAGE analysis, under reducing conditions, of the puriﬁed
protein revealed a single band with a molecular mass of 55.6 kDa
consistent with the calculated from its amino acid sequence (52.9
kDa without the signal sequence; Supplementary Figure 8a). The
oligomeric state of the puriﬁed 1D8N/CEGa1 was examined by
SEC-MALS measurements. The sample eluted as a major sym-
metric peak with a mass of 160 kDa, close to the calculated mass
for a trimer without the signal sequence (158.7 kDa), and a
minor peak with a mass of 309 kDa (Supplementary Figure 8b),
which is indistinguishable from 1D8N/CEGa1 by SDS-PAGE
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Fig. 1 Schematic diagrams of 4-1BB-agonistic trimerbodies. Protein
structure of the anti-4-1BB IgG (a) and the gene layout (left) and protein
structure (right) of monospeciﬁc (b) and bispeciﬁc trimerbodies (c). The
variable regions derived from 1D8 antibody are represented in orange, the
anti-EGFR VHH EGa1 in violet, the structural domains in light blue, and the
linker regions in gray. The 1D8 scFv-based N-terminal trimerbodies’ (1D8N)
gene constructs (b) contain a signal peptide from oncostatin M (white box)
and the 1D8 scFv gene (VL-VH) connected directly or through ﬂexible
linkers to the mouse TIEXVIII domain. In the bispeciﬁc 1D8N/CEGa1
trimerbody (c), the anti-human EGFR VHH EGa1 is fused to the C-terminus
of 1D8N18 through a ﬂexible linker. Arrows indicate the direction of
transcription. His6-myc tag (green box) and FLAG-strep tags (dark blue
box) were appended for immunodetection
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07195-w ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:4809 | DOI: 10.1038/s41467-018-07195-w |www.nature.com/naturecommunications 3
(Supplementary Figure 8c). These results again indicate the for-
mation of a minor population of dimers of trimers, as seen for
1D8N18. The two oligomeric species can be separated by SEC, and
reinjection of the isolated major peak of trimers yields only a very
minor peak at the elution volume of the trimer–dimers (Sup-
plementary Figure 8d). 1D8N/CEGa1 performed very similarly to
1D8N18 in CD and cooperative thermal denaturation studies
(Supplementary Figure 8e, f). SAXS showed that 1D8N/CEGa1
contains the same trimerized TIEXVIII core seen for 1D8N18. The
binding domains, however, are distributed evenly around the
plane deﬁned by the TIEXVIII core (Fig. 3a and Supplementary
Figure 8g, h, Supplementary Table 2), resembling a playground
roundabout. Using the SAXS data and structural information
from the protein data bank (PDB), we created a homology model
intended to clarify the layout of the six binding domains around
the core, as the linkers’ length and ﬂexibility permit several
conﬁgurations, e.g., with the three 1D8 scFvs opposite the three
EGa1 VHH (as shown in Fig. 3a), or with alternating 1D8 and
EGa1 domains side-by-side each other. Unfortunately, the
obtained resolution is insufﬁcient to distinguish between these
possibilities, although the overall hexagonal structure is clearly
deﬁned in the ab initio SAXS model.
The functionality of the 1D8N/CEGa1 was demonstrated by
BLI. The 1D8N/CEGa1 trimerbody has kinetic rate constants that
are very similar to the 1D8N trimerbodies in its interaction with
immobilized m4-1BB (Fig. 3b, Supplementary Table 1). The
binding kinetics of 1D8N/CEGa1 to immobilized human EGFR-Fc
chimera (hEGFR) was also investigated by BLI, and the
interaction was found to also have a low picomolar KD (Fig. 3b,
Supplementary Table 1). Our previous comparison of EGa1 VHH
and EGa1-derived N-trimerbody (EGa1N) kinetics showed a low
nanomolar KD for the EGa1 VHH and a low picomolar KD for
EGa1N 36. These kinetics are easily distinguishable, and 1D8N/
CEGa1 showed comparable kinetics to EGa1N, indicating that it
trivalently binds hEGFR. The 1D8N/CEGa1 was found to be
capable of binding immobilized m4-1BB and hEGFR simulta-
neously (Fig. 3c). This further demonstrates the bispeciﬁcity
of 1D8N/CEGa1 and shows a lack of steric hindrance between
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its interactions with hEGFR and m-4-1BB. The ability of
1D8N/CEGa1 to detect its antigens as cell surface proteins was
studied by ﬂow cytometry. The 1D8N/CEGa1 trimerbody bound
to HEK293 (EGFR+), to HEK293m4-1BB cells, and to mouse 3T3
cells expressing human EGFR (3T3hEGFR) but not to wild-type
3T3 cells (Supplementary Figure 9). Furthermore, 1D8N/CEGa1
bound to activated mouse CD8a+ T cells as efﬁciently as the
1D8N18 (Fig. 3d). To further assess the multivalent binding of
1D8N/CEGa1, we studied its capacity to inhibit proliferation and
EGFR phosphorylation in A431 cells32. 1D8N/CEGa1 and
cetuximab, an EGF-competitive inhibitor37, but neither the
anti-human CD20 rituximab nor 1D8 IgG, inhibited A431
proliferation, in a dose-dependent manner (P ≤ 0.0001 for the
higher doses of both antibodies, vs. equimolar doses of control
antibodies; Supplementary Figure 10a), and EGFR phosphoryla-
tion (Supplementary Figure 10b).
We then wanted to determine whether 1D8N/CEGa1 retained
the baseline costimulatory capacity seen for 1D8N18 and whether
this was improved by the crosslinking provided through EGa1’s
binding to hEGFR. CD8a+ T cells were stimulated with
immobilized anti-CD3 mAb and the panel of costimulatory
agents in solution, in the presence or absence of plastic-
immobilized hEGFR. The 1D8N/CEGa1 had a costimulatory
effect similar to 1D8N18 in the absence of hEGFR, but
proliferation (P = 0.0008) and IFN-γ levels (P = 0.0198) were
greatly enhanced when hEGFR was included (Fig. 3e, f). This
effect was further conﬁrmed by co-culture assays using EGFR-
negative and EGFR-positive target cells. The IFN-γ levels were
signiﬁcantly higher when CD8a+ T cells were co-cultured with
3T3hEGFR in the presence of the 1D8N/CEGa1, as compared to the
non-targeted 1D8 molecules (P = 0.0344 1D8 IgG, and P =
0.0009 1D8N18; Fig. 3g). We then investigated the effect of EGFR-
targeted 4-1BB costimulation on cell viability. After 72 h, a
statistically signiﬁcant increased viability of CD8a+ T cells
costimulated with 1D8N/CEGa1 in the presence of plastic-
immobilized hEGFR was observed (P = 0.0326), as compared
to cells costimulated with 1D8N18 (P = 0.0088; Fig. 3h).
The EGFR-targeted trimerbody shows high tumor localization.
First, we studied the serum stability of 1D8N18 and 1D8N/CEGa1,
and no signiﬁcant loss of 4-1BB- or EGFR-binding activity was
detected even after 7 days in mouse serum at 37 °C (Supple-
mentary Figure 11a, b). Pharmacokinetic studies were performed
in immunocompetent mice, which received a single intravenously
(i.v.) injection of the anti-4-1BB antibodies. The serum con-
centrations of active protein were determined by ELISA with
immobilized m4-1BB. In CD-1 mice, the 1D8N18 was rapidly
cleared from circulation with a terminal half-life of 1.3 h, whereas
the 1D8N/CEGa1 showed a prolonged circulatory half-life of
16.1 h (Fig. 4a, Supplementary Table 3). 1D8N/CEGa1 serum half-
life was not inﬂuenced by the genetic background of the mice, and
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a similar pharmacokinetic proﬁle was observed in BALB/c mice
(Fig. 4b, Supplementary Table 4). The half‐life of the anti-4-1BB
mAb 3H333was 4.8 days, consistent with published data38(Fig. 4b,
Supplementary Table 4). After a single intraperitoneal (i.p.)
injection in BALB/c mice, the half-lives of 1D8N/CEGa1 and 3H3
IgG were 32 h and 7 days, respectively (Fig. 4c, Supplementary
Table 5). For in vivo imaging, 3H3 IgG, 1D8N/CEGa1, and the
anti-EGFR mAb cetuximab were labeled with near-infrared (NIR)
ﬂuorochromes, which did not change their SDS-PAGE migration
or compromise their binding to cell surface antigen (Supple-
mentary Figure 12). Athymic nude mice bearing hEGFR-positive
A431 tumor xenografts subcutaneously (s.c.) implanted into the
right ﬂank were i.v. injected in the tail vein with NIR-labeled
antibodies and imaged 24 h later (Fig. 4d). The 1D8N/CEGa1
trimerbody showed high tumor localization with a tumor to
normal tissue (T/N) ratio of 4.85 ± 0.13 (mean ± SD), as com-
pared to that of cetuximab (2.54 ± 0.34) (P ≤ 0.01) and 3H3 IgG
(1.29 ± 0.06) (P ≤ 0.0001), which corresponds to little to no
speciﬁc tumor accumulation (Fig. 4d, e).
Antitumor activity of EGFR-targeted 4-1BB-agonistic trimer-
body. To study the antitumor effects of the EGFR-targeted 4-
1BB-agonistic trimerbody in immune competent mice, we used
murine CT26 colorectal carcinoma (H-2d) cells infected with
retrovirus encoding human EGFR (CT26hEGFR) (Supplementary
Figure 13a). The in vitro cell proliferation rates and the in vivo
take rate and growth curves in BALB/c mice of CT26hEGFR cells
and CT26mock cells infected with empty vector retroviruses were
similar (Supplementary Figure 13b, c), suggesting that the
expression of hEGFR did not signiﬁcantly alter the poor immu-
nogenicity of the CT26 tumor cells. Furthermore, ex vivo isolated
CT26hEGFR cells from 3-week-old s.c. tumors expressed sig-
niﬁcant levels of surface hEGFR (Supplementary Figure 13d). To
elucidate the functionality of the EGFR pathway in CT26hEGFR
cells, we studied the capacity of cetuximab and 1D8N/CEGa1 to
inhibit their proliferation. As shown in Supplementary Figure
13e, neither cetuximab nor 1D8N/CEGa1 had a signiﬁcant effect
on CT26hEGFR proliferation (P = 0.6647 and P = 0.0760
respectively, for higher dose, vs. equimolar dose of control anti-
body). Therefore, the potential therapeutic effect of 1D8N/CEGa1
is not contributed by an EGa1-mediated antiproliferative effect.
We used an established regimen to administer IgG-based 4-1BB-
agonistic mAbs and the EGFR-targeted 4-1BB-agonistic trimer-
body, with three i.p. injections at 2-day intervals15. Injection of
puriﬁed 1D8N/CEGa1 in mice bearing established CT26hEGFR
tumors (average diameter of 0.4 cm) induced tumor regression in
8 out of 10 (80%) mice in two separate experiments (Fig. 5a, b).
Treatment with the IgG-based 4-1BB agonist antibodies 1D8
(Fig. 5a) or 3H3 (Fig. 5b) resulted in complete regression in 10
out of 11 (91%) mice bearing CT26hEGFR tumors. All mice treated
with phosphate-buffered saline (PBS), control antibodies (isotype
control rat IgG2a and MFE-23N18), and 1D8N18 were sacriﬁced
within 4–5 weeks after tumor cell implantation (Fig. 5a, b). It is
well established that mice cured by IgG-based 4-1BB-agonistic
mAb treatment have long-lasting and tumor-speciﬁc immu-
nity39–41. To investigate whether the EGFR-targeted 4-1BB-
agonistic trimerbody can generate a similar effect, mice that
rejected the implanted CT26hEGFR tumor by treatment with 3H3
IgG or 1D8N/CEGa1 (Fig. 5b) were rechallenged 50 days later
with CT26mock cells. 3H3 IgG- and 1D8N/CEGa1-cured mice
(P = 0.0027 and P = 0.0067, respectively), but not age-matched
naive mice, were resistant to a rechallenge with CT26mock tumor
cells (Fig. 5c and Supplementary Figure 14), showing that the
trimerbody-mediated EGFR-targeted 4-1BB costimulation can
induce long-term protective immunological memory against
CT26 tumors that do not express hEGFR. In order to understand
the antitumor immune response generated with 4-1BB anti-
bodies, tumors from 3H3 IgG- and 1D8N/CEGa1-treated
mice and control mice were extracted 2 days after receiving the
third i.p dose (day 13 after tumor inoculation) (Supplementary
Figure 15) for immunohistochemistry to quantify tumor-
inﬁltrating CD8 + T lymphocytes (TILs). The percentage of
CD8+ TILs was an order of magnitude higher in 3H3 IgG- and
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Fig. 5 Induction of tumor regression in mice treated with 1D8N/CEGa1 trimerbody. a BALB/c mice inoculated s.c. with CT26hEGFR tumor cells (n = 6/group)
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1D8N/CEGa1-treated mice (19.48 ± 1.28 and 16.25 ± 1.41,
respectively) compared to the PBS-treated mice (1.42 ± 0.36)
(Fig. 5d and Supplementary Figure 16), indicating an efﬁcient
tumor recruitment of CD8+ T lymphocytes in the antibody-
treated mice.
EGFR-targeted 4-1BB-agonistic trimerbody shows negligible
toxicity. We compared the toxicity proﬁle of 1D8N/CEGa1
directly with 3H3 IgG under similar conditions. Mice were
injected i.p. with PBS, 3H3 IgG, or 1D8N/CEGa1 (6 mg/kg) once a
week for 3 weeks and euthanized 1 week later. As shown in
Fig. 6a, treatment with 3H3 IgG resulted in gross enlargement of
spleen and livers as demonstrated by weight (P ≤ 0.0001 and P =
0.0058, respectively). In contrast, treatment with 1D8N/CEGa1 did
not result in splenomegaly or hepatomegaly (Fig. 6a). The his-
tologic study of the spleens of mice treated with 3H3 IgG revealed
an altered architecture with expanded follicles with undeﬁned
zones and clear evidence of extramedullary hematopoiesis
(Fig. 6b), as previously described14. In contrast, the spleens of
mice treated with 1D8N/CEGa1 showed normal histology
(Fig. 6b). Also conﬁrming previous results14,15, treatment with
3H3 IgG caused signiﬁcant mononuclear cell inﬁltration in the
liver, forming periportal cuffs with thickening of tunica media
and also inﬁltration foci associated with microvasculature, while
no signiﬁcant inﬁltration was observed in mice treated with
1D8N/CEGa1 (Fig. 6b). Indeed, the surface of inﬁltrating mono-
nuclear cells accounted for 8% of the liver of mice treated with
3H3 IgG, while it only represented 0.6% in mice treated with
1D8N/CEGa1 (P = 0.0048) and 0.25% in mice treated with PBS
(P = 0.0104) (Fig. 6c). In addition, staining of collagen ﬁbers with
sirius red (Supplementary Figure 17) or Masson's trichrome
(Supplementary Figure 18) showed that 3H3 IgG treatment, but
not 1D8N/CEGa1, caused the deposition and disarrayment of
portal collagen ﬁbers, indicative of an early stage of ﬁbrosis.
Mononuclear cell inﬁltration was also seen in the lungs, forming
perivascular cuffs, and in pancreas of 3H3 IgG-treated mice.
Pancreas inﬁltration radiated from the vasculature and extended
to the neighboring intercalated ducts (Fig. 6b). Prominent col-
lagen deposition in the inﬁltrated areas of the pancreas of mice
treated with 3H3 IgG was observed, indicative of ﬁbrosis. In
contrast, none of these features were observed in mice treated
with 1D8N/CEGa1 (Supplementary Figure 17 and 18). The effects
of treatment with 3H3 IgG and 1D8N/CEGa1 on the levels of pro-
inﬂammatory cytokines in serum were also compared. As shown
in Fig. 6d, 3H3 IgG treatment triggered signiﬁcant elevation of
INF-γ, IL-6, and TNF-α (P = 0.0055 PBS, and P = 0.0015 1D8N/
CEGa1), particularly evident at day 21. In contrast, 1D8N/CEGa1
induced minimal or undetectable levels of inﬂammatory cyto-
kines comparable to PBS-treated animals.
In order to investigate whether 1D8N/CEGa1’s shorter half-life
might be responsible for its lack of toxicity, another study was
conducted in BALB/c mice in which 1D8N/CEGa was adminis-
tered (6 mg/kg) i.p. every 3 or 4 days, for 3 weeks, for a total of six
doses. These more frequent injections were intended to maintain
circulatory levels of 1D8N/CEGa1 comparable to those of the
longer-circulating 3H3 IgG, which was injected as before with 6
mg/kg i.p injections once weekly for 3 weeks. The escalated 1D8N/
CEGa1 regimen did not induce splenomegaly or hepatomegaly,
nor signiﬁcant histological alterations, while the standard 3H3
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CEGa1. b Hematoxylin and eosin staining of representative tissue slides from the spleen, liver, pancreas, and lung of mice treated with PBS, 3H3 IgG, and
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IgG regimen induced alterations similar to those observed in 3H3
IgG-treated C57BL/6 mice (Supplementary Figure 19).
Discussion
In this study, we describe a tumor-targeted 4-1BB agonist tri-
merbody with similar efﬁcacy and less toxicity than conventional
IgG-based 4-1BB-agonistic antibodies. This hexavalent trimer-
body consists of three anti-4-1BB scFvs and three anti-EGFR
single-domain antibodies organized around a modiﬁed homo-
trimerization domain from collagen XVIII. More than 80% of its
mass is directly involved in antigen binding. While the mono-
speciﬁc trivalent 1D8N18 trimerbody adopts a tripod-shaped
conformation, the addition of the anti-EGFR VHH antibodies into
the bispeciﬁc hexavalent 1D8N/CEGa1 trimerbody changes the
conformation to an extended and planar hexagram-shaped
structure with the six binding domains exposed at the periph-
ery. This structure is inherently ﬂexible, and the SAXS ab initio
model supports a dynamic equilibrium of the open conformation
where the binding domains are not locked into place relative to
the core but instead exist in various extended conformations.
These structural ﬁndings, when considered alongside the high
avidity observed in characterization of 1D8N/CEGa1’s binding to
biosensor- and cell surface-displayed 4-1BB, indicate that the
binding domains are predominantly sterically unhindered and
available for antigen binding.
The 1D8N/CEGa1 trimerbody is efﬁciently expressed by
transfected human cells as soluble protein and can be puriﬁed
using standard afﬁnity chromatographic methods. SEC-MALS
showed that both 1D8N18 and 1D8N/CEGa1 trimerbodies pri-
marily formed the expected trimeric structure, with a minor
fraction forming higher-order oligomers (likely trimer–dimers).
This effect was not observed with either EGa1 VHH-based
trimerbodies36,42or non-1D8 scFv-based trimerbodies31,43and is
therefore likely attributable to the 1D8 scFv. The partial dimer-
ization of scFvs44and clustering behavior of certain scFvs in
particular45have previously been reported, so this is not a new
phenomenon.
The binding experiments provide quantitative evidence for
trimeric interactions between the 1D8N/CEGa1 trimerbody and
both EGFR and 4-1BB. This 3:3 stoichiometry of the 1D8N/
CEGa1 trimerbody is unique among the existing body of 4-1BB-
binding proteins, including 4-1BBL fusion proteins25. We have
provided evidence that, upon binding of soluble 4-1BBL to cell
surface-displayed 4-1BB, the complex is rapidly internalized,
whereas the anti-4-1BB antibodies induced the formation of
durable clusters. The amount and stability of the 4-1BB clusters
are signiﬁcantly higher upon interaction with trivalent 1D8N18
trimerbody than with bivalent 1D8 IgG, and this, along with the
increased avidity for EGFR, could explain the increased costi-
mulation induced by 1D8N/CEGa1. The bispeciﬁc trimerbody
demonstrated better costimulation of CD8a+ T cells in the pre-
sence of human EGFR, either immobilized or expressed in a cell
surface context. These results support the 1D8N/CEGa1
trimerbody-induced formation of dense, clustered 4-1BB signal-
ing complexes at the point of contact between a T cell and a TAA-
displaying surface. The need for 4-1BB crosslinking beyond tri-
merization (i.e., hyper-crosslinking) has previously been reported
as necessary for inducing strong 4-1BB signaling20.
Besides the potent tumor-speciﬁc costimulation, the 1D8N/
CEGa1 trimerbody exhibit improved serum stability as well as
efﬁcient and rapid localization to EGFR-positive tumors. The
1D8N/CEGa1 trimerbody may be able to maximize tumor-speciﬁc
costimulation due to the combination of a higher total tumor
uptake and substantially faster circulatory clearance, ultimately
giving an improved T/N ratio as compared to conventional IgG-
based anti-EGFR and anti-4-1BB antibodies. The magnitude of
the protective antitumor response provided by the EGFR-targeted
4-1BB-agonistic trimerbody is equivalent to that observed for two
well-characterized anti-4-1BB mAbs, 1D8 and 3H333. We show
that the administration of the 1D8N/CEGa1 trimerbody can era-
dicate established CT26hEGFR tumors. Furthermore, rechallen-
ging of the mice that rejected the tumor upon treatment with
EGFR-targeted 4-1BB-agonistic trimerbody with fresh CT26mock
cells failed to allow tumor implantation, thus indicating that long-
lasting tumor-speciﬁc memory had been established. In this
study, the 4-1BB agonists were administered intraperitoneally,
using a treatment regimen that has been validated for IgG-based
anti-4-1BB antibodies15. Despite its signiﬁcantly shorter terminal
half-life, the 1D8N/CEGa1 trimerbody showed similar efﬁcacy to
1D8 and 3H3 mAbs, indicating that its quicker clearance is
compensated for by other factors, potentially improved tumor
retention due to higher avidity, and more extensive tumor
penetration due to its structure. As 1D8N/CEGa1 did not induce
toxicity even when circulating at high concentrations for a 3-week
period, half-life extension strategies can be explored, such as
inclusion of albumin fragments or albumin-binding moieties46.
The mechanism of action of IgG-based 4-1BB-agonistic anti-
bodies has been interpreted as a consequence of enhanced anti-
tumor CD8+ T cell responses47, and as the percentage of
inﬁltrating CD8+ T cells is similar in 3H3 IgG- and 1D8N/
CEGa1-treated mice, it is likely that both IgG-based anti-4-1BB
antibodies and tumor-targeted 4-1BB agonist trimerbody act in a
mechanistically equivalent manner.
Toxicity has been the major impediment for ﬁrst-generation 4-
1BB-agonistic mAbs. In preclinical murine models, systemic
administration of IgG-based anti-4-1BB antibodies resulted in
nonspeciﬁc immune stimulation and other immune-related
anomalies that affected the function of organs such as the liver,
spleen, and bone marrow14,48. Similarly to these mouse studies,
clinical trials using urelumab have been associated with adverse
effects at higher doses, such as liver toxicity that resulted in two
fatalities16. Here we show that treatment of naive immuno-
competent mice with the IgG-based anti-4-1BB-agonistic anti-
body resulted in severe toxicity, as assessed by enlarged spleen
and liver, severe inﬂammation and ﬁbrosis in the liver, spleen and
pancreas, and systemic inﬂammatory cytokine production.
Treatment with an EGFR-targeted 4-1BB-agonistic trimerbody
lacked these immune-related side effects, even after an escalated
regimen doubling the number of injections. Our study suggests
that these immunological abnormalities and organ toxicities are
mainly dependent on FcR interactions.
In summary, bispeciﬁc trimerbodies have been effectively
applied to the treatment of established tumors by tumor-targeted
4-1BB costimulation and comprise a novel technology platform
for the future development of this and similar immunother-
apeutic approaches, e.g., tumor-speciﬁc costimulation through
CD40 or OX40, and combining PD-L1 blocking with costimu-
latory strategies. The EGFR-targeted 4-1BB agonist trimerbody
described in this study was successfully implemented from its
design, as it had the desired structure, function, and stability. In
vivo, it did not show the toxicities that have been associated with
IgG-based 4-1BB agonist and have notoriously held them back in
clinical trials. Our results emphasize the need for future studies
with non-canonical immunotherapeutic antibodies in order to
realize the therapeutic potential of 4-1BB costimulation.
Methods
Mice. C57BL/6, BALB/c, Hsd:ICR (CD-1), and Hsd:athymic Nude-Foxn1nu
female mice were purchased from Harlan Iberica. Animals were housed in con-
trolled conditions of temperature (21 ± 1 °C), humidity (50 ± 5%), and 12 h light/
dark cycles. Manipulation was performed in laminar ﬂow hood, when necessary,
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and sterilized water and food were available ad libitum. All animal procedures
conformed to European Union Directive 86/609/EEC and Recommendation 2007/
526/EC, enforced in Spanish law under RD 1201/2005. Animal protocols were
approved by the respective Ethics Committee of Animal Experimentation of the
participant institutions: Instituto Investigación Sanitaria Puerta de Hierro-Segovia
de Arana (Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain),
Intituto de Investigaciones Biomédicas “Alberto Sols” (IIBm) (CSIC-UAM,
Madrid), and Laboratory Animal Applied Research Platform (Parc Cientíﬁc, Bar-
celona, Spain). Procedures were additionally approved by the Animal Welfare
Division of the Environmental Affairs Council of the Government of Madrid (66/
14, 430/15, 264/16) and by the Ethics Committee of the Catalonian authorities
(9912).
Cells and culture conditions. HEK293 (CRL-1573), NIH/3T3 (CRL-1658), and
A431 (CRL-1555) cells were obtained from ATCC and were grown in complete
Dulbecco’s modiﬁed Eagle’s medium (DMEM) at 37 °C. HEK293 cells expressing
m4-1BB (HEK239m4-1BB)49were cultured in complete DMEM+500 µg/ml G418.
NIH/3T3 cells expressing human EGFR (3T3hEGFR) were provided by Dr A. Vil-
lalobo (IIBm, Madrid)50. Mouse CT26 cells (CRL-2638) infected with p-BABE-
puro-hEGFR51expressing human EGFR (CT26hEGFR) or infected with the empty
vector retrovirus (CT26mock) were provided by Dr M. Rescigno (European Institute
of Oncology, Milan)37. The cell lines were routinely screened for mycoplasma
contamination by PCR (Stratagene).
Construction of expression vectors. A synthetic gene encoding the 1D8 scFv was
synthesized by Geneart AG and subcloned as ClaI/NotI into pCR3.1-L36-
NC131resulting in pCR3.1-1D8-TIE18. To obtain the plasmids pCR3.1-1D8-TIE0
and pCR3.1-1D8-TIE5, two synthetic genes encoding the 1D8 scFv gene fused
directly or by a 5-mer ﬂexible linker to the N-terminus of the mouse TIEXVIII
domain were synthesized by Geneart AG and subcloned as PstI/XbaI into pCR3.1-
1D8-TIE18. To generate the bispeciﬁc trimerbody-expressing vector, the BamHI/
XbaI fragment, containing the EGa1 gene, from pCR3.1-EGa1-TIE7 44 was ligated
into pCR3.1-1D8-TIE18 to obtain pCR3.1-1D8N18-TIE-C18EGa1-myc/His. In order
to introduce a N-terminal FLAG-StrepII tag, the HindIII/NotI fragment from
pCR3.1-FLAG-StrepII-1D8-TIE18-iRGD was ligated into pCR3.1-1D8N18-TIE-
C18EGa1-myc/His to obtain pCR3.1-FLAG-StrepII-1D8N18/C18EGa1-myc/His. The
C-terminal myc/His tag was removed by PCR with LEGA-1 and Stop-XbaI-Rev
primers (Supplementary Table 6) to generate pCR3.1-FLAG-StrepII-1D8N18/
C18EGa1. The sequences were veriﬁed with Fw-CMV and Rv-BGH (Supplementary
Table 6).
Expression and puriﬁcation of recombinant antibodies. HEK293 cells were
transfected with the appropriated vectors and selected in complete DMEM+500 μg/ml
G418 to generate stable cell lines. Recombinant antibodies were puriﬁed from condi-
tioned media with HisTrap HP columns or with the (Twin-) Strep-tag puriﬁcation
system (IBA Lifesciences). Endotoxin levels were <0.25 EU/ml as determined by the
LAL Endotoxin Kit (Pierce).
Western blotting. Samples were separated under reducing conditions on 10–20%
Tris-glycine gels and transferred onto nitrocellulose membranes and probed with
either anti-c-myc (9E10, cat#ab206486, Abcam) or anti-FLAG (M2, cat#F480,
Sigma-Aldrich) mAbs (1 µg/ml), followed by incubation with DyLight800-goat
anti-mouse (GAM) IgG (1:5000 dilution) (cat#610-145-121, Rockland Immuno-
chemicals). Visualization of protein bands was performed with the Odyssey® sys-
tem (LI-COR Biosciences).
Enzyme-linked immunosorbent assay. Mouse 4-1BB:hFc chimera (m4-1BB;
cat#937-4B-050, R&D Systems) and human EGFR:hFc chimera (hEGFR;
cat#ab155726, Abcam) were immobilized (3 µg/ml) on Maxisorp plates (NUNC
Brand Products) overnight at 4 °C. After washing and blocking, conditioned media
or puriﬁed protein solution (1 µg/ml) were added and incubated for 1 h at room
temperature. The wells were washed and anti-c-myc mAb or anti-FLAG mAb
added (1 µg/ml). After washing, horseradish peroxidase (HRP)-GAM IgG (1:1000
dilution) (cat#A5278, Sigma-Aldrich) or HRP-goat anti-rat (GAR) IgG (1:1000
dilution) (cat#ab97057, Abcam) were added, and the plate was developed using O-
phenylenediamine dihydrochloride (OPD). For competition ELISA, m4-1BB
(3 µg/ml) was immobilized, and after blocking, m4-1BBL (cat#754402, Biolegend)
was added at 4.27 nM for 1 h. Puriﬁed antibody solution (4.27 nM) was serially
two-fold diluted, added to the wells, and incubated for 1 h. After washing, anti-
FLAG mAb (1 µg/ml) was added for 1 h. After washing, HRP-GAM IgG (1:1000
dilution) was added and developed.
Flow cytometry. The cells were incubated for 1 h with puriﬁed antibodies (6.67
nM), washed, incubated for 30 min with anti-His (BMG-His-1, cat#11922416001,
Roche Life Science) anti-c-myc or anti-FLAG mAbs (1 µg/ml), and were detected
with a phycoerythrin (PE)-GAM IgG F(ab’)2 antibody (1:200 dilution) (cat#115-
116-072, Jackson Immuno Research). The 1D8 IgG (M. Jure-Kunkel, Bristol-Myers
Squibb) and cetuximab (Merck KGaA) (6.67 nM) were used as controls, using PE-
GAM IgG F(ab′)2 (1:200 dilution) and PE-goat anti-human IgG F(ab′)2 (1:50
dilution) (cat#109-116-097, Jackson Immuno Research), respectively. Samples were
analyzed with a MACSQuant Analyzer 10 (Miltenyi Biotec GmbH). For compe-
tition studies, puriﬁed mouse CD8a+ T cells were activated for 48 h with
concanavalin-A (5 µg/ml), blocked with human γ-globulin for 5 min, incubated
with 10 µg/ml 1D8 IgG for 20 min on ice, and washed with PBS thereafter, while
the other samples were left untreated. Then cells were incubated with 2 µg/ml of
1D8 IgG, 1D8N18, 1D8N5, or rat IgG2a for 20 min on ice and washed. Next, cells
that were incubated with 1D8N18 or 1D8N5 and one untreated control sample was
incubated with rabbit anti-c-myc mAb (1:200 dilution) (A-14; cat#sc789, Santa
Cruz Biotechnology). Finally, cells were incubated with either Alexa 647-GAR IgG
or donkey anti-rabbit IgG (1:100 dilution) (cat#A-21247 and A-31573, Molecular
Probes) together with ﬂuorescein isothiocyanate (FITC)-anti-mouse CD8 mAb
(1:500 dilution) (53-6.7; cat#553030, BD Pharmigen) for 20 min. Samples were
analyzed with FACSCanto II and FACSort ﬂow cytometers (BD Biosciences). To
generate HEK293 cells homogeneously expressing high levels of 4-1BB
(HEK293m4-1BB-S), HEK293m4-1BB cells were stained with PE-anti-mouse CD137
mAb (1:1000 dilution) (17B5; cat#106105, Biolegend) and sorted using a FACSAria
II (BD Biosciences).
Mass spectrometry. A 2 μl protein sample was desalted using ZipTip® C4 micro-
columns (Merck Millipore) and eluted with 0.5 μl sinapinic acid (10 mg/ml in
[70:30] Acetonitrile: Triﬂuoroacetic acid 0.1%) matrix onto a GroundSteel massive
384 target (Bruker Daltonics). An Autoﬂex III MALDI-TOF/TOF spectrometer
(Bruker Daltonics) was used in linear mode with the following settings:
5000–40,000 Th window, linear positive mode, ion source 1: 20 kV, ion source 2:
18.5 kV, lens: 9 kV, pulsed ion extraction of 120 ns, high gating ion suppression up
to 1000 Mr. Mass calibration was performed externally with protein 1 standard
calibration mixture (Bruker Daltonics). Data acquisition, peak peaking, and sub-
sequent spectra analysis was performed using the FlexControl 3.0 and FlexAnalysis
3.0 software (Bruker Daltonics).
Size exclusion chromatography with multi-angle light scattering. Static light
scattering experiments were performed at room temperature using a Superdex 200
Increase 10/300 GL column (GE Healthcare) attached in-line to a DAWN-
HELEOS light scattering detector and an Optilab rEX differential refractive index
detector (Wyatt Technology). The column has an exclusion volume of 8.6 ml, and
no absorbance (no aggregated protein) was observed in any of the injections. The
column was equilibrated with running buffer (PBS+150 Mm NaCl) and the SEC-
MALS system was calibrated with a sample of bovine serum albumin (BSA) at 1 g/l
in the same buffer. Then 100 μl samples of the two antibodies 1D8N18 and 1D8N/
CEGa1 at 1 g/l in the running buffer were injected into the column at a ﬂow rate of
0.5 ml/min. Data acquisition and analysis were performed using the ASTRA
software (Wyatt Technology). The reported molar mass corresponds to the center
of the chromatography peaks. After separation of the monomeric species by SEC a
second injection in the SEC-MALS system was done at 0.26 g/l. Based on
numerous measurements on BSA samples at 1 g/l under the same or similar
conditions, we estimate that the experimental error in the molar mass is around
5%.
Circular dichroism. Circular dichroism measurements were performed with a
Jasco J-810 spectropolarimeter (JASCO). The spectra were recorded on protein
samples at 0.2 g/l in PBS using 0.2 cm path length quartz cuvettes at 25 °C.
Thermal denaturation curves from 10 to 95 °C were recorded on the same protein
samples and cuvette by increasing temperature at a rate of 1 °C/min and measuring
the change in ellipticity at 218 nm.
Small-angle X-ray scattering. SAXS experiments were performed at the beamline
B21 of the Diamond Light Source (Didcot, UK). The proteins were concentrated
and prepared at 4 °C prior data collection. Samples of 40 μl of 1D8N18 and 1D8N/
CEGa1 at concentrations of 3 and 6 mg/ml were delivered at 4 °C via an in-line
Agilent 1200 HPLC system in a Shodex Kw-403 column, using a running buffer
composed by 50 mM Tris pH 7.5+150 mM NaCl. The continuously eluting
samples were exposed for 300 s in 10 s acquisition blocks using an X-ray wave-
length of 1 Å and a sample to detect (Pilatus 2M) distance of 3.9 m. The data
covered a momentum transfer range of 0.032 < q < 3.695 Å−1. The frames recorded
immediately before elution of the sample were subtracted from the protein scat-
tering proﬁles. The Scatter software package (www.bioisis.net) was used to analyze
data, buffer-subtraction, scaling, merging, and checking possible radiation damage
of the samples. The data set corresponding to 1D8N18 at 3 mg/ml could not be
further analyzed due to aggregation. The Rg values were calculated with the Guinier
approximation assuming that at very small angles q < 1.3/Rg. The maximum
particle distribution, Dmax, and the distance distribution were calculated from the
scattering pattern with GNOM, and shape estimation was carried out with
DAMMIF/DAMMIN, and all these programs are included in the ATSAS pack-
age52. Interactively generated PDB-based models were made for the two antibodies
based in templates obtained with the program RaptorX. Real-space scattering
proﬁles of the models were computed with the program FoXS.
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Kinetic measurements using BLI. The interactions between immobilized m4-1BB
and 1D8 IgG, 1D8N18, 1D8N5, and 1D8N0 were investigated on an Octet
RED96 system (Fortebio). Mouse 4-1BB was immobilized onto AR2G biosensors
(Fortebio) using 10 µg/ml of m4-1BB in 10 mM acetate buffer at pH 6, over 20 min,
to a signal of 1.8 ± 0.4 nm. The kinetics experiment for each antibody used 4
unregenerated m4-1BB-coated biosensors, 2 of which were associated with 4 nM of
antibody in kinetics buffer (PBS+0.1% BSA+0.05% Tween 20), and 2 with 2 nM.
Association was run for 1 h, followed by 3 h of dissociation in analyte-free kinetics
buffer. The acquired sensorgrams were globally ﬁt to a 1:1 model using the Octet
Data analysis software. Kinetics experiments were performed at 37 °C while shaken
at 1000 rpm. The avidity of the interaction between immobilized hEGFR and
analyte 1D8N/CEGa1 was investigated similarly. The hEGFR was immobilized onto
AR2G biosensors using 3 µg/ml of hEGFR in 10 mM acetate buffer at pH 5.
Association and dissociation were both measured for 2 h. To demonstrate the
ability of 1D8N/CEGa1 to bind both of its antigens in tandem, m4-1BB was
immobilized onto AR2G biosensors, and 4 nM of 1D8N/CEGa1 or 1D8N18 were
allowed to associate with 2 biosensors each for 1 h. The biosensors were brieﬂy
moved into kinetics buffer for 10 min, after which 1 biosensor loaded with each
antibody was moved into 10 nM hEGFR for 1 h while the other biosensor remained
in kinetics buffer. Finally, all biosensors were moved into kinetics buffer for 1 h.
Serum stability. Puriﬁed antibodies were incubated in human serum at 37 °C, for
at least 7 days. The binding activity of the sample at 0 h was set as 100% in order to
calculate the time corresponding to percentage of decay in binding activity.
T cell costimulation assays. Goat anti-hamster IgG (cat#127-005-160, Jackson
ImmunoReserach) was pre-coated overnight at 4 °C in 96-well plates (5 µg/ml),
and after blocking, anti-CD3 mAb (145-2C11; cat# MO3PU(V100), Immunostep)
(1 µg/ml) was added and incubated at 37 °C for 1 h. Mouse CD8a+ T cells were
puriﬁed from the spleens of C57BL/6 mice using the EasySep™Mouse CD8a+T Cell
Isolation Kit (Stem Cell Technologies). Then puriﬁed mouse CD8a+ T cells (2.5 ×
105/well) in complete RPMI+50 µM 2-mercaptoethanol, and puriﬁed antibodies at
6.67 nM were added. As a control, puriﬁed mouse CD8a+ T cells were cultured
alone with the immobilized anti-CD3 mAb (1 µg/ml). After 48 h, cell proliferation
was assessed with the CellTiter-Glo luminescent assay (Promega) using a Tecan
Inﬁnite F200 plate-reading luminometer, and supernatants were collected and
assayed for IFN-γ secretion by ELISA (Diaclone). For viability assays, cells were
collected after 72 h, incubated with FITC-Annexin V (Immunostep) and 7-AAD
(BD Biosciences), and analyzed with a MACSQuant Analyzer 10. Results are
expressed as a mean ± SD from one of at least three separate experiments.
Antigen-speciﬁc T cell costimulation assays. For studies with puriﬁed hEGFR,
96-well plates were pre-coated with goat anti-hamster IgG (5 μg/ml) and hEGFR
(5 μg/well). After blocking, anti-CD3 mAb (1 µg/ml) was added and incubated for
1 h at 37 °C, before adding mouse CD8a+ T cells and the puriﬁed antibodies
(6.67 nM). For studies with cells, NIH/3T3 or 3T3hEGFR target cells were seeded
overnight. Next day, target cells were pre-incubated for 30 min on ice with puriﬁed
antibodies (6.67 nM). Mouse CD8a+ T cells were activated with biotin-anti-CD3
mAb (145-2C11, cat#100303, Biolegend) (100 ng/ml) cross-linked with streptavi-
din (1:5 molar ratio) and added at 10:1 effector/target ratio. As a control, mouse
CD8a+ T cells were cultured alone with plastic immobilized anti-CD3 mAb
(1 µg/ml). Cell proliferation and IFN-γ secretion were measured after 48 h, and cell
viability after 72 h. Results are expressed as a mean ± SD from one of at least three
separate experiments.
Inhibition of EGFR-mediated cell proliferation and signaling. A431 cells were
seeded in complete DMEM in 96-well plates. After 24 h, medium was replaced by
DMEM+1% fetal calf serum (FCS) containing equimolar concentrations
(0.19–50 nM) of cetuximab, rituximab (Hoffmann-La Roche Ltd.), 1D8N/CEGa1,
or 1D8 IgG and incubated for 72 h. Viability was assessed using the CellTiter-Glo
luminescent assay. Experiments were performed in triplicates. For EGFR signaling
studies, A431cells were starved overnight in DMEM+1% FCS and then incubated
for 4 h in serum-free DMEM in the presence of 0.1 µM cetuximab, rituximab,
1D8N/CEGa1, or 1D8 IgG, followed by incubation with 25 ng/ml of human EGF
(MiltenyiBiotec GmbH) for 5 min. After stimulation, cells were lysed in Laemmli-
lysis buffer, separated under reducing conditions on 4–12% Tris-glycine gels,
transferred to nitrocellulose membrane, and incubated with the rabbit anti-human
phosphor-EGFR (Tyr1068) mAb (1:1000 dilution) (D7A5; cat#3777, Cell Signaling
Technology Inc.) followed by incubation with an IRDye800CW-donkey anti-rabbit
antibody (1:5000 dilution) (cat#925-32213, LI-COR Biosciences). Simultaneously,
anti-β-actin mouse mAb (1:2000 dilution) (8226; cat#ab8226, Abcam) was added
as a loading control, followed by IRDye680RD-donkey anti-mouse IgG (1:5000
dilution) (cat#925-68072, LI-COR Biosciences). Visualization and quantitative
analysis of protein bands were carried out with the Odyssey system.
Antibody labeling. Puriﬁed 1D8 IgG, 1D8N18, and 4-1BBL were labeled with the
Mix-n-Stain CF488A Antibody Labeling Kit, and puriﬁed 3H3 IgG (cat#BE0239,
BioXCell) and 1D8N/CEGa1 were labeled with NIR ﬂuorochrome CF647 using the
Mix-n-Stain CF647 Antibody Labeling Kit according to the manufacturer’s
recommendations (Biotium). Cetuximab was labeled with NIR ﬂuorochrome
Cy5TM Mono NHS Ester (GE Healthcare) according to the manufacturer’s
recommendations. The degree of labeling (DOL) was determined from the
absorption spectrum of the labeled antibody; 1.5/1 and 2.7/1 dye/protein in the case
of CF488A- and CF647-labeled proteins, respectively. Cetuximab has a DOL of 2.3/
1 dye/protein.
Live cell receptor clustering imaging. HEK293m4-1BB-S cells were plated onto 35-
mm poly-L-lysine pre-coated dishes at a 50% conﬂuence, and after overnight
culture, the dishes were assembled in 35-mm diameter chambers (Ibidi GmbH)
with 600 μl of dichloromethane and set onto a Leica SP8 3X SMD microscope
(Leica Microsystems) under 37 °C and 5% CO2 conditions. The excitation wave-
length used was 488 nm from a white light laser (NKT Photonics A/S) with very
low power 2–5%, and the detection was from 500 to 550 nm. CF488A-labeled 1D8
IgG, 1D8N18, or 4-1BBL were extemporaneously added to the cells at a ﬁnal
concentration of 100 ng/ml, and RICS was performed. Characterization of the
microscope point spread function, i.e., the focal volume where the ﬂuorescent dyes
diffuse in and out, was done employing 2 μg/ml soluble puriﬁed EGFP
(Biovision)34. The series of images recorded for RICS were of 256 × 256 pixels, with
a pixel size of 80 nm, and employing 2-μs dwell time. RICS analysis and diffusion
coefﬁcient quantiﬁcation was done by employing the SIM FCS 4 software (G-SOFT
Inc.). Every time trace from the time series was carefully observed to avoid possible
artifacts due to dramatic photobleaching, which otherwise would affect the diffu-
sion coefﬁcient quantiﬁcation. By these means, we avoided employing detrending
algorithms that sometimes can bias the analysis. RICS analysis was performed
using a moving average (background subtraction) of ten to discard possible arti-
facts arising from cellular motion and slow-moving particles passing through. The
obtained two-dimensional autocorrelation map was ﬁtted to get the diffusion
surface map that was represented in three dimension. For the different region of
interest (ROI) analyses within the same cell, the corresponding region was drawn
employing a square region of 64 × 64 pixels. Selected regions were deﬁned as where
there was the presence or absence of receptor clustering. For statistical purposes,
each condition was studied on minimum ﬁve different cells, and in each cell a
minimum of three different ROIs were analyzed. Brightness and contrast of the
ﬂuorescence and differential interference contrast were optimized with the ImageJ
software. Diffusion values were represented in a whisker and box plot using Ori-
ginPro (OriginLab).
Pharmacokinetics study. Female CD-1 mice (n = 24/group) received a single i.v.
dose of 1D8N18 or 1D8N/CEGa1 (1 mg/kg), and blood samples from 3 mice per
group were collected at 5, 15, 30 min and 1, 3, 6, 24, and 48 h. Female BALB/C
mice were injected i.v. (n = 24/group) or i.p. (n = 6/group) with a single dose of
3H3 IgG or 1D8N/CEGa1 (1 mg/kg). Serial blood samples were obtained at dif-
ferent time points from 30 min to 264 h. Serum was obtained after centrifugation
and stored at −20 °C. Sera were analyzed for antibody concentration by ELISA
against immobilized m4-1BB (3 µg/ml). After washing and blocking, sera from
different time points were added and incubated for 1 h at room temperature. The
wells were washed and HRP-anti-c-myc (1 µg/ml) (cat#ab1326, Abcam), HRP-
anti-FLAG mAb (1 µg/ml) (M2; cat#ab49763, Abcam), or HRP-GAR IgG (1:1000
dilution) were added. After washing, the plates were developed using OPD.
Pharmacokinetic parameters were calculated using the Prism software (GraphPad
Software).
Molecular imaging in tumor-bearing mice. A431 cells (1 × 106) were implanted s.
c. into the dorsal space of 6-week-old female Hsd:athymic Nude-Foxn1nu mice.
Tumor growth was monitored two times a week by measuring the diameter of the
tumors with a calliper, and tumor volumes were calculated according to the for-
mula: Volume = (D × d2/2), where D is the longest axis of the tumor and d is the
shortest of a prolate ellipse. When tumor volume reached about 0.180 cm3, mice
were randomly allocated to different treatment groups (n = 3/group) and i.v.
injected with PBS or NIR-labeled antibody solution (1 mg/ml) in PBS. Mice were
imaged under anesthesia at 24 h under the IVIS Spectrum CT in vivo imaging
system (Xenogen) at the indicated wavelengths and were analyzed using the Living
Image 3.2 software (PerkinElmer). The images were analyzed by identifying 3 ROIs
within the tumor and from surrounding regions (normal tissue). The T/N ratio was
calculated by dividing the mean values of the identiﬁed ROIs. Fluorescence
intensity of all the images are reported as photons per second per centimeter
squared per steradian (p/s/cm2/sr).
Therapeutic studies. CT26hEGFR cells (1.5 × 106) were implanted s.c. into the
dorsal space of 6-week-old female BALB/c mice. Tumor growth was monitored by
calliper measurements three times a week, and when tumors reached approxi-
mately 0.4 cm in diameter (usually from 7 to 10 days), mice were randomized to
receive treatment (n = 5 or 6/group). Measurements were conducted in a random
order by the investigator who was blinded to the treatment assignment. Mice were
treated every other day with three i.p. injections of PBS, anti-4-1BB antibodies, or
control antibodies (4 mg/Kg). Mice were euthanized when tumor size reached a
diameter of 1.5 cm any dimension, when tumors ulcerated, or at any sign of mouse
distress. To study the long-lasting systemic immune-mediated response, surviving
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mice (n = 5) were re-challenged with CT26mock cells (1.5 × 106) s.c. in the con-
tralateral left ﬂank 50 days following treatment with 3H3 IgG or 1D8N/CEGa1.
Cured and naive mice were followed for an additional 190 days after reinoculation.
Immunohistochemistry. CT26hEGFR tumors from different treatment groups were
collected after 13 days of implantation and ﬁxed in 10% neutral buffered formalin
(Sigma-Aldrich) for 48 h. Then, after extensive washing in PBS, tissues were
embedded in parafﬁn, cut at 3 µm, mounted in Superfrost®plus slides, and dried
overnight. Slides were deparafﬁned in xylene and re-hydrated through a series of
graded ethanol washes, ending in a ﬁnal rinse in pure water. Slides were incubated
with a rat monoclonal anti-CD8a (1:200 dilution) (OTO94A; Monoclonal Anti-
bodies Core Unit CNIO) followed by a rabbit anti-rat secondary antibody
(cat#ab6703, Abcam) and a visualization system (Novolink Polymer anti-Rabbit,
Leica) conjugated with HRP. Nuclei were counterstained with Harris’ hematoxylin.
Positive control sections known to be primary antibody positive were included for
each staining run. Whole digital slides were acquired with a slide scanner
(AxioScan Z1, Zeiss), and total versus positive cells were automatically quantiﬁed
(AxioVision 4.6 software package, Zeiss).
Toxicity studies. Three-month-old female C57BL/6 received a weekly i.p. dose of
3H3 IgG or 1D8N/CEGa1 (6 mg/kg) for 3 weeks. Mice were anesthetized and bled
on days 0, 7, 14, and 21. To obtain mouse serum, blood was incubated in BD
microtainer SST tubes (BD Biosciences), followed by centrifugation. Serum was
stored at −20 °C until use. One week after the last dose of antibodies, mice were
euthanized and the liver, spleens, lungs, and pancreas were surgically removed,
weighted, and ﬁxed in 10% paraformaldehyde for 48 h. Then ﬁxed tissues were
washed and embedded in parafﬁn. Tissue sections (5 µm) were stained with
hematoxylin and eosin, Sirius red, or Masson's trichrome (Sigma-Aldrich) for
collagen staining. Lymphocyte inﬁltration in the liver was quantiﬁed using the
ImageJ software. A similar study was performed in 2-month-old female BALB/c
mice, but in this case the 1D8N/CEGa1 was injected i.p. every 3/4 days (6 mg/kg)
for 3 weeks. The 3H3 IgG was administered with the same regimen: a weekly i.p.
injection (6 mg/kg) for 3 weeks.
Luminex assay. Blood was collected from the treated mice on the indicated days,
and the levels of inﬂammatory cytokines (IFN-γ, IL-6, TNF-α) in serum samples
were determined using a Luminex Milliplex Magnetic Bead Kit (Merck Millipore).
Statistical analysis. Statistical analysis was performed using the GraphPad Prism
Software version 5.0. All the in vitro experiments were done in triplicates and
values are presented as mean ± SD from one of at least three separate experiments.
Signiﬁcant differences (P value) were discriminated by applying a two-tailed,
unpaired Student’s t test assuming a normal distribution with *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001. To assess differences in tumor growth, tumor diameter for individual
mice in each treatment group are presented. Survival curves for the different
treatment groups were created using the Kaplan–Meier method, and two or more
survival curves were analyzed using log-rank (Mantel–Cox) test. For the other
in vivo studies, data were presented using a scatter plot as mean ± SD, and P values
were determined by unpaired Student’s t test to assess the differences between
treatment groups.
Data availability
The authors declare that the data supporting this study are available within the
paper and its Supplementary Information File. All other data are available from the
authors upon reasonable request.
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